http://orcid.org/0000-0001-5036-0336
Figures & data
Figure 1. Evolution of epidemiological trends of outbreaks from 1990 to 2015.
Dengue serotypes distribution: data based on 174 outbreaks including 80 from 2010 (46%) outbreaks distribution among WHO regions: data based on 262 outbreaks including 112 from 2010 (43%) (data from GUO et al, 2017).
Figure 2. CYD-TDV (Dengvaxia®) vaccine.
The tetravalent dengue vaccine CYD-TDV has been constructed by substituting prM and E genes from DENV-1 to DENV-4 into the backbone of the molecular clone of yellow fever vaccine YF-17D. there are four chimeric CYD-1 to CYD-4 which compose the CYD-TDV.
Figure 3. TDV vaccine candidate.
The Takeda tetravalent vaccine TDV has been generated by substituting prM and E genes from DENV-1, DEN-3, and DENV-4 into TDV-2 backbone. TDV2 is an over-attenuated mutant of DENV-2 vaccine candidate DENV-2-PDK53.
Figure 4. LAV Delta 30 vaccine candidate.
The tetravalent dengue vaccine LAV Delta 30 (or TV003) is composed of four mutants DENV-1 to DEN-4 which contain a deletion of 30 nucleotides (∆30) in the domain II of the 3ʹNTR of their genomic RNA. mutant DENV-4 virus ∆30 was used as a backbone to generate a chimeric DENV-2 virus ∆30 by substitution of the prM and E genes.
